CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of ...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate ...
-Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone- -Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON ...
CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and ...
(RTTNews) - BioVie Inc. (BIVI) on Wednesday announced the initiation of patient enrollment in its Phase 2 SUNRISE-PD clinical trial, evaluating bezisterim or NE3107 in patients with early-stage ...
SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results